Research Conducted at Northeast Agriculture University Has Provided New Information about Immunotherapy (Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy)
By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Data detailed on Biotechnology have been presented. According to news originating from Harbin, People's Republic of China, by NewsRx correspondents, research stated, "Newcastle disease virus (NDV) is an intrinsically tumor-specific virus, several clinical trials have reported that mesogenic NDV is a safe and effective agent for human cancer therapy. Interleukin 2 (IL2) is a cytokine that stimulates T cell propagation to trigger innate and adaptive immunity."
Our news journalists obtained a quote from the research from Northeast Agriculture University, "IL2 has been used for cancer therapy and has achieved curative effects. In this study, a recombinant NDV LaSota strain expressing human interleukin 2 (rLaSota/IL2) was generated. The ability of rLaSota/IL2 to express human IL2 was detected in the infected tumor cells. In addition, the activity of IL2 was analyzed. The antitumor potential of rLaSota/IL2 was studied by xenograph mice carrying H22 and B16-F10 cells. Tumor-specific CD4(+) and CD8(+) T cells and MHC II were also analyzed in the two tumor-bearing models. Our study showed that rLaSota/IL2 significantly stimulated tumor-specific cytotoxic T-lymphocyte (CTL) responses and increased regulatory CD4(+) and cytotoxic CD8(+) T cells proliferation. The treatment with rLaSota/IL2 led to tumor regression in tumor-bearing mice and prolonged the survival of tumor-bearing mice. Furthermore, tumor challenging experiments demonstrated that rLaSota/IL2 invoked mice a unique capacity to remember a pathogen through the generation of memory T cells, which protect the host in the event of reinfection and form adaptive immune system. The result indicates that tumor-infiltrating CD4(+) T regulatory cells may denote the effective regression of tumors."
According to the news editors, the research concluded: "Taken together, rLaSota/IL2 has potential for immunotherapy and oncolytic therapy of cancers and may be an ideal candidate for clinical application in future cancer therapy."
For more information on this research see: Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy. Immunology Letters, 2014;159(1-2):36-46. Immunology Letters can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Immunology Letters - www.elsevier.com/wps/product/cws_home/506020)
The news correspondents report that additional information may be obtained from F.L. Bai, Northeast Agr Univ, Biopharmaceut Teaching & Res Sect, Coll Life Sci, Harbin 150030, People's Republic of China. Additional authors for this research include Z.S. Niu, H. Tian, S.M. Li, Z. Lv, T.Y. Zhang, G.P. Ren and D.S. Li (see also Biotechnology).
Keywords for this news article include: Asia, Biotechnology, Pharmaceuticals, Harbin, Cancer, Oncology, Peptides, Proteins, Cytokines, Engineering, Lymphokines, RNA Viruses, Bird Diseases, Immunotherapy, Interleukin-2, Drug Development, Immunomodulation, Newcastle Disease, Avulavirus Infections, People's Republic of China, Paramyxoviridae Infections
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC